摘要
为了探讨肾移植后患者全血ＣｓＡ谷浓度（ＴＬ）与临床的关系，寻求适合国人肾移植受者ＣｓＡ理想治疗窗浓度范围。应用ＦＰＩＡ法特异性单克隆试剂盒测定口服ＣｓＡ１２小时后全血谷浓度。结果表明，肾移植后在应用标准三联免疫抑制治疗中，ＣｓＡ理想治疗窗浓度范围应为：术后第１个月全血ＣｓＡＴＬ为３５０～４５０μｇ／Ｌ；第２个月为２５０～３５０μｇ／Ｌ；第３个月为２５０～３００μｇ／Ｌ；第４个月以后ＣｓＡＴＬ应维持在１５０～２５０μｇ／Ｌ范围内。此浓度范围既能达到满意的免疫抑制效果，又能减少ＣｓＡ的肝、肾毒性作用及排斥反应。因此，可视为国人肾移植受者ＣｓＡ的理想治疗窗浓度范围。
In renal transplant recipients on triple immunosuppressants regimen, the CsA trough level 12 hours after its oral administration was assayed by means of FPIA with the use of specific monoclone reagent kits. The ideal satisfactory immunosuppressive CsA trough levels were found as follows: The whole blood CsA trough level was 350～450μg/L within the first month after transplantation, 250～350μg/L in the second month, 250～300 in the third month and within the range of 150～250 since then. The aforementioned range of therapeutic window concentration of CsA trough levels were claimed to be ideal for Chinese renal transplant recipients with no marked toxic effects to the liver and kidney.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
1998年第2期67-69,共3页
Chinese Journal of Urology
